During preclinical studies, L19-IL-2 demonstrated an excellent tumor–to–blood ratio of 33:1 24 h post injection, and the ratio between the percentage of injected dose per gram of tumor and other organs exceeded the value of 10. Here, IL2 is linked to neoplasm.